Cargando…

Rotavirus Vaccine Impact since Its Introduction in the National Immunization Program of Argentina

INTRODUCTION: Rotavirus (RV) is the most common cause of childhood diarrhea. Argentina introduced RV vaccination in the National Immunization Program in January 2015. This study evaluates the impact of RV vaccine implementation on the burden of acute diarrheal disease (ADD) and RV positive cases, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Marti, Sebastian Garcia, Gibbons, Luz, Reidel, Sara, Stupka, Juan, Degiuseppe, Juan, Argento, Fernando, Gómez, Jorge A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925648/
https://www.ncbi.nlm.nih.gov/pubmed/36520328
http://dx.doi.org/10.1007/s40121-022-00709-6
_version_ 1784888104822243328
author Marti, Sebastian Garcia
Gibbons, Luz
Reidel, Sara
Stupka, Juan
Degiuseppe, Juan
Argento, Fernando
Gómez, Jorge A.
author_facet Marti, Sebastian Garcia
Gibbons, Luz
Reidel, Sara
Stupka, Juan
Degiuseppe, Juan
Argento, Fernando
Gómez, Jorge A.
author_sort Marti, Sebastian Garcia
collection PubMed
description INTRODUCTION: Rotavirus (RV) is the most common cause of childhood diarrhea. Argentina introduced RV vaccination in the National Immunization Program in January 2015. This study evaluates the impact of RV vaccine implementation on the burden of acute diarrheal disease (ADD) and RV positive cases, and hospitalizations among children in Argentina. METHODS: A counterfactual time-series analysis was performed. Data on ADD (2013–2018) and RV diarrhea (2012–2018) cases in children aged < 5 years were collected from the National Healthcare Surveillance System (clinical and laboratory data). Data on hospital discharges following ADD and RV diarrhea (2011–2017) were retrieved from the Health Statistics and Information Office. All data were classified by the age groups < 1 year, < 2 years, 2–5 years. Vaccine impact was defined as the difference between the predicted time trend (simulated using 2012–2014 data) and the actual post-vaccination data (2015–2018). RESULTS: A significant reduction of 22.1% of notified ADD cases and 15.4% of hospital discharges following ADD among children < 2 years was observed in the 3 years after RV vaccine implementation. Data also showed a significant decline of 54.0% and 59.4% of notified RV cases in children < 2 and < 1 years, respectively, and a reduction of 39.3% and 40.8% in RV hospital discharges for the same age groups. CONCLUSION: This study shows a significant reduction in notified ADD cases and RV cases and hospital discharges following ADD and RV cases in children < 2 years after RV vaccine introduction in Argentina in 2015. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-022-00709-6.
format Online
Article
Text
id pubmed-9925648
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-99256482023-02-15 Rotavirus Vaccine Impact since Its Introduction in the National Immunization Program of Argentina Marti, Sebastian Garcia Gibbons, Luz Reidel, Sara Stupka, Juan Degiuseppe, Juan Argento, Fernando Gómez, Jorge A. Infect Dis Ther Original Research INTRODUCTION: Rotavirus (RV) is the most common cause of childhood diarrhea. Argentina introduced RV vaccination in the National Immunization Program in January 2015. This study evaluates the impact of RV vaccine implementation on the burden of acute diarrheal disease (ADD) and RV positive cases, and hospitalizations among children in Argentina. METHODS: A counterfactual time-series analysis was performed. Data on ADD (2013–2018) and RV diarrhea (2012–2018) cases in children aged < 5 years were collected from the National Healthcare Surveillance System (clinical and laboratory data). Data on hospital discharges following ADD and RV diarrhea (2011–2017) were retrieved from the Health Statistics and Information Office. All data were classified by the age groups < 1 year, < 2 years, 2–5 years. Vaccine impact was defined as the difference between the predicted time trend (simulated using 2012–2014 data) and the actual post-vaccination data (2015–2018). RESULTS: A significant reduction of 22.1% of notified ADD cases and 15.4% of hospital discharges following ADD among children < 2 years was observed in the 3 years after RV vaccine implementation. Data also showed a significant decline of 54.0% and 59.4% of notified RV cases in children < 2 and < 1 years, respectively, and a reduction of 39.3% and 40.8% in RV hospital discharges for the same age groups. CONCLUSION: This study shows a significant reduction in notified ADD cases and RV cases and hospital discharges following ADD and RV cases in children < 2 years after RV vaccine introduction in Argentina in 2015. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-022-00709-6. Springer Healthcare 2022-12-15 2023-02 /pmc/articles/PMC9925648/ /pubmed/36520328 http://dx.doi.org/10.1007/s40121-022-00709-6 Text en © GSK 2022 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Marti, Sebastian Garcia
Gibbons, Luz
Reidel, Sara
Stupka, Juan
Degiuseppe, Juan
Argento, Fernando
Gómez, Jorge A.
Rotavirus Vaccine Impact since Its Introduction in the National Immunization Program of Argentina
title Rotavirus Vaccine Impact since Its Introduction in the National Immunization Program of Argentina
title_full Rotavirus Vaccine Impact since Its Introduction in the National Immunization Program of Argentina
title_fullStr Rotavirus Vaccine Impact since Its Introduction in the National Immunization Program of Argentina
title_full_unstemmed Rotavirus Vaccine Impact since Its Introduction in the National Immunization Program of Argentina
title_short Rotavirus Vaccine Impact since Its Introduction in the National Immunization Program of Argentina
title_sort rotavirus vaccine impact since its introduction in the national immunization program of argentina
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925648/
https://www.ncbi.nlm.nih.gov/pubmed/36520328
http://dx.doi.org/10.1007/s40121-022-00709-6
work_keys_str_mv AT martisebastiangarcia rotavirusvaccineimpactsinceitsintroductioninthenationalimmunizationprogramofargentina
AT gibbonsluz rotavirusvaccineimpactsinceitsintroductioninthenationalimmunizationprogramofargentina
AT reidelsara rotavirusvaccineimpactsinceitsintroductioninthenationalimmunizationprogramofargentina
AT stupkajuan rotavirusvaccineimpactsinceitsintroductioninthenationalimmunizationprogramofargentina
AT degiuseppejuan rotavirusvaccineimpactsinceitsintroductioninthenationalimmunizationprogramofargentina
AT argentofernando rotavirusvaccineimpactsinceitsintroductioninthenationalimmunizationprogramofargentina
AT gomezjorgea rotavirusvaccineimpactsinceitsintroductioninthenationalimmunizationprogramofargentina